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Abstract 
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare heterogenous genetic or acquired hyperinflam-
matory syndrome associated with a high degree of morbidity and mortality. HLH has clinical manifestations related to 
abnormal prolonged activation of T lymphocytes and macrophages with an excess of proinflammatory cytokines. The 
main causes of secondary HLH are malignancies and infectious diseases.
Case presentation: The patient was a 54-year-old man, originally from Eastern Africa, who had lived in Northern 
Europe for 30 years. Here we describe the clinical features, laboratory parameters, diagnostic workup, manage-
ment and outcome data of a previously healthy 54-year-old man diagnosed with HLH secondary to tuberculosis. 
The patient was initially treated for a community-acquired pneumonia. He developed multiorgan failure with acute 
respiratory distress syndrome, hypertransaminasemia, and kidney and bone marrow dysfunction. The clinical course 
together with a simultaneous increase in serum ferritin raised the suspicion of HLH. The patient fulfilled seven out 
of eight diagnostic criteria for HLH. A thorough diagnostic workup with respect to HLH and a potential underlying 
disease was initiated. Cultivation of bronchoalveolar lavage fluid, stool and urine, and polymerase chain reaction of 
epithelioid cell granulomas in the bone marrow were all positive for Mycobacterium tuberculosis. He was treated for 
both HLH and tuberculosis, and he survived without any sequelae.
Conclusions: We present one of few published cases of a patient who survived HLH triggered by miliary tuberculo-
sis. The current case illustrates the need for awareness of these two diagnoses, and the timely initiation of specific and 
supportive treatment to reduce mortality.
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is an 
uncommon hematologic disorder characterized by an 
uncontrolled immune response with organ infiltration of 
lymphocytes and histiocytes, and organ damage caused 
by excessive production of pro-inflammatory cytokines 
[1–6]. HLH is categorized either as primary due to a 
genetic disorder, or as secondary due to an acquired con-
dition. Secondary HLH can be triggered by neoplastic 
and non-neoplastic diseases [7]. Malignancies associated 
with secondary HLH are mainly various hematological 
malignancies such as leukemia or lymphoma, whereas 
autoimmune disorders and infectious diseases are the 
most common nonmalignant diseases associated with 
HLH [3, 8]. While active tuberculosis (TB) is rare in 
the Nordic countries, the World Health Organization 
estimates 10 million new TB cases globally causing 1.5 
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million deaths every year, thus making Mycobacterium 
tuberculosis the single most lethal infectious agent in the 
world [9, 10]. HLH due to TB is very uncommon, with 
only a few cases reported, mostly in immunocompro-
mised patients [8, 11–13].
Here we report a case of HLH associated with miliary 
TB in an apparently immunocompetent healthy man. 
The case illustrates that the combination of an aggressive 
diagnostic approach, searching for a broad variety of dis-
orders, combined with an early therapeutic intervention 
are crucial to securing a successful outcome.
Case presentation
The patient was a 54-year-old man, originally from 
Eastern Africa, who had lived in Northern Europe for 
30  years. Apart from increased blood pressure, caus-
ing mild left ventricle hypertrophy, he was healthy and 
only taking antihypertensive medication. He contacted 
his family physician due to nausea and loose, yellow-
ish stools. Due to dysuria and microhematuria, he had 
received treatment with orally administered mecillinam 
for a suspected urinary tract infection. As this treat-
ment had no effect, he was given doxycycline on suspi-
cion of respiratory tract infection due to dyspnea and 
fever. Eventually, he was admitted to the hospital after 
10 days of nausea, anorexia, diarrhea, frequent micturi-
tion, dyspnea, persistent fever, increasing C-reactive pro-
tein (CRP) and elevated liver transaminases. He had no 
cough, night sweats or weight loss. On clinical examina-
tion on admission, he was alert and oriented, but hypo-
tensive (blood pressure 102/58 mmHg) and hypoxic with 
 SpO2 of 86% without supplemental oxygen. The respon-
sible clinician described mild scleral jaundice, but no 
rashes or palpable adenopathy. Pulmonary auscultation 
revealed bilateral crackles. Laboratory test values showed 
hemoglobin level of 15.4 g/dL (reference 13.4–17.0), leu-
kocyte count at 10.4  109/L (ref 3.5–11.0) and thrombo-
cytes at 220  109/L (ref 145–348). CRP was elevated at 
118  mg/L (ref < 5). Erythrocyte sedimentation rate was 
not taken at admission. He had acute kidney failure with 
creatinine at 297 µmol/L (ref 60–105), and elevated liver 
transaminases with alanine aminotransferase of 208 U/L 
(ref 10–70), alkaline phosphatase 191 U/L (ref 35–105), 
gamma-glutamyltransferase 337 U/L (ref 15–115) and 
bilirubin 26  µmol/L (ref < 20) (Fig.  1). He had severely 
reduced partial pressure of oxygen in arterial blood 
to the inspired oxygen ratio  (paO2/FiO2) at 31.3  kPa 
(ref 55–65) (Fig.  2). Computed tomography (CT) scan 
revealed ground-glass opacities in both lungs, extensive 
unspecific changes in the colon, multiple enlarged para-
aortic lymph nodes, fat tissue reaction in the posterior 
abdominal wall (Fig. 3), an enlarged liver at 19 cm in the 
midclavicular line with rounded margins, and a slightly 
enlarged spleen at 14 cm.
On admission, the clinical presentation was not clear-
cut, and the attending clinician considered the possibil-
ity of viral or bacterial infections, including pneumonia 
(fever, dyspnea, auscultatory crackles), possibly due to 
atypical agents, as well as urinary tract infection, hepa-
titis, intra-abdominal infection, gastroenteritis with 
ensuing hemolytic uremic syndrome, and a variety of 
noninfectious diseases including renal failure due to 
Fig. 1 Development in biochemical parameters during the disease 
course. Day 0 is the first day of hospitalization, and the timing of 
various diagnostic and prognostic approaches are marked in the 
graph
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dehydration, vasculitis, other systemic diseases, heart 
failure and thromboembolism. Broad-spectrum anti-
biotic (piperacillin-tazobactam) was started  to cover 
for bacterial infection of unknown origin. No clinical 
improvement was observed the following week, and due 
to increasing respiratory failure, he was transferred to 
the nearest regional university hospital for bronchoscopy 
and further diagnostics. Piperacillin-tazobactam was 
given from admission and meropenem from day 7, with 
the addition of azithromycin from day 9 for a suspected 
bacterial etiology, but without any clinical or biochemi-
cal improvement. He developed increasing respiratory 
failure that required noninvasive ventilation from day 7, 
and progressive hypoxemia necessitated intubation at day 
10. Continuous renal replacement therapy was initiated 
from day 11 due to increasing kidney failure as evidenced 
by decreasing diuresis, metabolic acidosis and increasing 
serum creatinine levels (Figs. 1, 2). Despite lung protec-
tive ventilatory support, the  paO2/FiO2 rapidly deterio-
rated (Fig.  2). On day 11 after admission, the attending 
clinicians started treatment with high dosages of corti-
costeroids to cover for a possible autoimmune etiology.
At this point, the diagnostic assessment had not 
revealed the cause of the severe clinical course. Standard 
workup for infectious diseases with culturing of blood, 
urine and stools did not reveal the etiology. Serologi-
cal tests for human immunodeficiency virus (HIV) and 
hepatitis A and B were all negative. Serology revealed 
prior but not active infection with Epstein–Barr virus 
(EBV) and cytomegalovirus (CMV). Since the patient 
had been back in his homeland 1 year prior to hospi-
talization, tropical infectious diseases with long incuba-
tion time were considered. With fever, pancytopenia and 
splenomegaly, he displayed the cardinal signs of visceral 
leishmaniasis, but microscopy of blood and bone marrow 
aspirate did not reveal visible Leishmania amastigotes, 
serology was negative and polymerase chain reaction 
Fig. 2 Oxygenation  (paO2/FiO2 ratio) and ventilation (pH) during 
the intensive care unit (ICU) stay. Time is marked as hours after 
ICU attendance. The arrow marks the start time point for steroid 
treatment
Fig. 3 Radiological examination of the patient. Computed tomography scan images of the abdomen taken at admission demonstrating enlarged 
spleen and liver, lymphadenopathy in the abdomen, thickened wall of colon and bile duct, and atelectasis in the lung sections
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(PCR) of blood could not detect Leishmania DNA. Serol-
ogy for strongyloides was also negative. Considering the 
febrile illness with pulmonary opacities, respiratory fail-
ure and subacute deterioration of multiple organ sys-
tems, miliary TB was recognized as a possible diagnosis. 
Interferon gamma release essay (IGRA,  QuantiFERON®) 
taken at admission was positive at a medium level at 
1.98 IU/mL. Upon transfer to the regional hospital, a new 
IGRA test was taken with negative/inconclusive results, 
with a value of 0.21  IU/mL, and a repeat test showed a 
gray zone result of 0.39  IU/mL (reference values  nega-
tive < 0.26, gray zone 0.26–0.43, low  positive  0.44–0.69, 
medium positive 0.70–3.99, strong positive ≥ 4.00). No 
immunosuppressive treatment had been given at this 
point. Direct microscopy of bronchial fluid obtained by 
bronchoscopy did not show acid-fast bacilli, and PCR 
on the same specimen was negative for Mycobacterium 
tuberculosis.
However, these findings could not exclude TB infec-
tion. Therefore, the patient was given therapy with 
rifampicin and isoniazid intravenously, and pyrazinamide 
on nasogastric tube, against possible TB infection at the 
same time as  steroids were started. Intravenous levo-
floxacin was added to cover for other potential bacterial 
infections. Although levofloxacin also has antimycobac-
terial properties, it is not part of standard first-line anti-
TB treatment.
An exceptionally rapid improvement of the respira-
tory failure was seen after initiating treatment with 
high dosage of steroids and tuberculostatic drugs 
(Fig.  2). The kidney failure continued, however, and 
the bone marrow failure was worsening, with rapidly 
decreasing thrombocyte and white blood cell count 
(WBC) (Fig. 1). Since admission, the patient had persis-
tent fever, increasing levels of serum ferritin to a maxi-
mum value of 17,000  µg/L (ref 34–300), splenomegaly 
and increasing pancytopenia, in addition to hypertri-
glyceridemia with serum triglycerides of 5.2  mmol/L 
(ref 0.45–2.60). Based on these clinical and laboratory 
findings, a diagnosis of HLH was suspected (Table  1). 
Two weeks after admission, blood tests were analyzed 
for soluble IL-2 receptor and natural killer (NK)-cell 
activity, and bone marrow biopsy was performed. An 
eliciting cause for HLH was sought. Tests for antinu-
clear antibody (ANA) and antineutrophil cytoplasmic 
antibody (ANCA) were both negative. Immunophe-
notyping of bone marrow showed no evidence of lym-
phoproliferative diseases with T- or B-cell clonality. 
Lymphadenopathy of the posterior abdominal wall and 
wall thickening of the colon seen on CT scan at admis-
sion disappeared after initiation of corticosteroid ther-
apy, and biopsy was no longer possible.
At day 10, the patient fulfilled five out of eight diagnos-
tic criteria for HLH (fever, splenomegaly, bi-cytopenia, 
hypertriglyceridemia and hyperferritinemia), and treat-
ment with etoposide 75  mg/m2 was initiated according 
to the HLH-2004 protocol [14], although with 50% dose 
reduction due to cytopenia and hyperbilirubinemia, 
and without cyclosporine A (Fig. 1). Over the next days 
a rapid improvement of the kidney function, decrease 
in serum ferritin levels and improvement of the general 
condition were observed (Fig. 1). All anti-TB drugs were 
discontinued, as all tests for TB apart from the interferon-
gamma release assay remained negative, and TB was con-
sidered less likely. Levofloxacin was continued. Three 
weeks after admission, however, culture of bronchial 
fluid, stool and urine revealed M. tuberculosis and was 
also positive on the antigen MPT64 assay, confirming the 
diagnosis of TB. Results from bone marrow biopsy later 
revealed an expanded erythropoiesis, increased number 
of histiocytic cells with phagocytosed lymphocytes and 
nuclear debris (hemophagocytosis) and granulomas that 
supported the diagnosis of HLH and TB, respectively 
(Fig. 4). The bone marrow was also later found to be posi-
tive for M. tuberculosis by PCR. Level of  IL-2 receptor 
was increased to 15,000 U/mL (ref 45–1100), and NK-cell 
Table 1 The diagnostic criteria for hemophagocytic lymphohistiocytosis with definitions
Hb hemoglobin, ANC absolute neutrophil count, SD standard deviation, NK natural killer
Findings Definitions Present
Fever Peak temperature of > 38.5 °C for > 7 days X
Splenomegaly Spleen palpable > 3 cm below costal margin X
Cytopenia Involving > 2 cell lines; Hb < 9.0 g/dL, ANC < 1.0 × 109/L, platelets < 100 × 109/L X
Hypertriglyceridemia or hypofibrinogenemia Fasting triglycerides > 2.0 mmol/L or > 3 SD more than normal value for age or fibrino-
gen < 1.5 g/L or > 3 SD less than normal value for age
X
Hemophagocytosis Hemophagocytosis demonstrated in biopsy samples of bone marrow, spleen or lymph nodes X
Low or absent NK cell activity Reduced NK cell activity as measured by standardized assay
Hyperferritinemia Serum ferritin > 500 ng/mL X
Elevated soluble interleukin-2 (CD25) levels CD25 level > 2400 U/mL X
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activity was slightly above the normal range at 64% (ref 
18–59).
Taken together, the patient met seven out of eight diag-
nostic criteria for HLH as stated by the HLH-2004 trial 
(Table 1) [14]. Miliary TB was regarded as the triggering 
factor. The TB isolate was likely susceptible to rifampicin 
and isoniazid, the most important first-line anti-TB 
drugs, as line-probe assay (GenoType MTBDRplus, Hain 
Lifescience) showed no mutations conveying resist-
ance to rifampicin or isoniazid in the rpoB, katG and 
inhA genes. Thus, the patient received standard anti-TB 
treatment with rifampicin, isoniazid, pyrazinamide and 
ethambutol, in the form of four-drug fixed-dose combi-
nation tablets (FDCs) [15].
Treatment of secondary HLH is directed against the 
underlying disease; however, initial treatment with ster-
oids and/or immunosuppressants is usually required 
to prevent rapidly progressing organ damage and 
death. Etoposide was discontinued after 3 weeks due 
to increasing cytopenia, while steroids were continued 
with tapering doses every 14 days over a 6-week period 
(Fig. 1). Towards the end of the hospital stay the patient 
received 5  days of additional treatment with intrave-
nously administered ceftriaxone, due to a febrile con-
dition probably related to neutropenia (neutrophils at 
0.1  109/L). His general clinical condition was rapidly 
improving, and after 1  month of hospitalization he 
was discharged with biochemical recovery including 
decreasing serum ferritin. In light of the severe initial 
disease, the initial-phase anti-TB-treatment with four-
drug FDCs was extended for a total of 3 months, and 
the subsequent continuation-phase treatment with 
two-drug FDCs containing rifampicin and isoniazid 
was given for 6  months, for a total treatment dura-
tion of 9 months. On subsequent outpatient visits, the 
patient’s condition has continuously improved, and 
he is currently without any sequela or signs of active 
disease.
Fig. 4 Histopathological features of the bone marrow. The figure demonstrates bone marrow findings for the patient with hematoxylin and 
eosin staining. a Overview of the bone marrow demonstrating hypercellular bone marrow with bone marrow cellularity of approximately 70%. 
b Encircled area displays groups of epithelioid cells consistent with granulomas. c Higher resolution demonstrating epitheliod cell granulomas 
located within the bone marrow. d Demonstrating granuloma with several giant cells present. e A significantly expanded erythropoiesis. f Several 
macrophages with intracytoplasmic residues of nuclear fragments consistent with hemophagocytosis (arrows)
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Discussion
HLH is a life-threatening immune syndrome caused 
by the massive production of cytokines due to a highly 
stimulated but ineffective immune response. The patho-
genesis of HLH is complicated and not completely under-
stood, but secondary hyperactivation of macrophages 
and CD8+ T lymphocytes in the absence of regula-
tory NK cell activity seems essential. This results in the 
massive production of proinflammatory cytokines that 
directly provokes end organ damage [1–6]. The diagno-
sis of HLH is challenging and can often be overlooked or 
delayed. As no single diagnostic test exists, the diagnos-
tic criteria applied in the HLH-2004 trial are currently 
used to diagnose HLH (Table  1). Hyperferritinemia is 
often the first clue to the diagnosis. Although the diag-
nostic criteria consider ferritin > 500  µg/L as diagnostic, 
the ferritin levels are often considerably more elevated 
[16], as was the case for our patient presenting with 
serum ferritin increasing to > 17,000  µg/L. If additional 
cytopenias are present, involving at least two lines, this 
should clearly raise the clinical suspicion of HLH. Our 
patient developed thrombocytopenia and anemia, which 
led to further investigation for suspected HLH. Fasting 
hypertriglyceridemia and/or hypofibrinogenemia can 
also quite easily be detected, while assays for soluble IL-2 
receptor and NK cell activity are often not readily avail-
able in standard hospital laboratories. A biopsy demon-
strating hemophagocytosis is of considerable help, as 
in our patient (Fig.  2). Bone marrow biopsies are easily 
obtained, and mandatory to rule out secondary causes of 
HLH such as underlying malignant disorders or visceral 
leishmaniasis.
The etiology of HLH can be categorized as primary 
and secondary causes (Table  2). Primary HLH is very 
rare in adults and is caused by loss of function in genes 
associated with vesicle trafficking in cytotoxic T and/
or NK cells [17]. This results in reduction or loss of the 
cytotoxic potential in NK and T cells, and inability of the 
immune system to sufficiently eliminate activated mac-
rophages [18, 19]. Although primary HLH is caused by 
an underlying genetic immunodeficiency, clinical pres-
entation is usually triggered by a viral infection, most 
commonly EBV [20]. Secondary HLH can be triggered 
by both malignant and nonmalignant diseases (Table  2) 
[21]. Malignant disorders often associated with second-
ary HLH include hematological malignancies such as 
lymphoma, acute leukemias and myelodysplastic syn-
drome, but the syndrome has also been observed in rela-
tion to solid tumors [22]. The nonmalignant conditions 
associated with HLH can be broadly divided into autoim-
mune disorders and infectious diseases. Among autoim-
mune disorders we find diseases such as systemic lupus 
erythematosus (SLE), systemic-onset juvenile idiopathic 
arthritis (Still’s disease) and rheumatoid arthritis. The 
most common infections reported to be associated with 
HLH include EBV, leishmaniasis, CMV, HIV and fungal 
infections [12], and most recently SARS-CoV-2 [23]. The 
association between TB and HLH has been described 
previously. However, most of the cases described are 
in immunocompromised patients, including patients 
with concomitant malignant disorders, HIV, patients on 
hemodialysis and renal transplant recipients [11].
Diagnosis of pulmonary TB is rapid and straightfor-
ward when acid-fast bacilli can be seen on direct micros-
copy. However, negative microscopy does not rule out 
TB. Extrapulmonary TB is particularly challenging to 
diagnose, as direct microscopy and PCR have low sen-
sitivity on specimens such as pus, cerebrospinal fluid, 
biopsies and lymph nodes. Although TB bacteria are 
present throughout the lungs in miliary TB, the major-
ity of these patients have no visible acid-fast bacilli on 
sputum microscopy. As in our case, definitive diagno-
sis of microscopy-negative TB relies on a culture for M. 
tuberculosis, which may take up to 6–8 weeks to become 
Table 2 Classification of HLH
MDS myelodysplastic syndrome, GI tract gastrointestinal tract, UG tract urogenital tract SLE systemic lupus erythematosus, EBV Epstein–Barr virus, CMV 
cytomegalovirus, HIV human immunodeficiency virus, TB tuberculosis
Primary HLH Secondary HLH
Malignant Nonmalignant
Hematological malignancies Solid tumors Autoimmune Infectious
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positive. While PCR has high specificity and can rapidly 
identify M. tuberculosis, its sensitivity is far inferior to 
culture.
The classical description of miliary TB is that of hema-
togenous seeding occurring successively after primary 
infection and resulting in millet-like grains in various 
organs, including the lungs, where these grains result in 
typical findings on chest X-ray. Pathological examina-
tion typically shows granulomas, as was found on the 
bone marrow specimen from our patient, and is highly 
suggestive of the diagnosis. The term cryptic miliary TB 
is sometimes used to describe similar seeding occurring 
later in conjunction with reactivated TB ("post-primary" 
TB), and tending to affect older individuals, often with-
out typical X-ray findings. A third form, nonreactive TB, 
describes widespread seeding of TB where there is dys-
functional immune response, allowing the bacteria to 
spread without formation of granulomas, and frequently 
without “miliary” characteristics on chest X-ray. Nonre-
active TB often occurs in immunocompromised patients, 
including HIV patients with low CD4 (cluster of differen-
tiation 4) counts. The term disseminated TB is often used 
interchangeably with miliary TB, but sometimes reserved 
for nonreactive TB or widespread TB without typical 
miliary findings on chest X-ray. The patient’s origin in a 
TB-endemic region suggested that he suffered from cryp-
tic miliary TB due to reactivation many years after pri-
mary infection. Nonreactive TB was unlikely, as he had 
granuloma formation on pathological examination, and 
no underlying immunosuppression could be found. The 
National Reference Laboratory for Mycobacteria (NRL) 
at the Norwegian Institute of Public Health performed 
phenotypical drug susceptibility testing using the BAC-
TEC MGIT 960 system (Becton Dickinson, NJ, USA), 
confirming susceptibility to all primary anti-TB drugs, 
as well as relatedness analysis with comparison to iso-
lates from patients diagnosed with TB in Norway during 
the last 8 years. Interestingly, MIRU-VNTR (mycobacte-
rial interspersed repetitive unit-variable number tandem 
repeat) typing first suggested that the isolate could be 
related to one obtained from a patient diagnosed with TB 
in Norway 3 years earlier, consistent with relatively recent 
primary infection causing classic miliary TB. However, 
whole-genome sequencing (on an Illumina platform) 
excluded relatedness to this isolate (in-house methodol-
ogy), supporting the initial theory of cryptic miliary TB 
caused by reactivation decades after primary infection.
Diagnostics of TB-triggered HLH is particularly chal-
lenging, as HLH and miliary TB have several features 
in common, particularly fever, splenomegaly and ane-
mia, but also lymphopenia, thrombocytopenia and ele-
vated ferritin. While anemia is seen in most miliary TB 
patients, only up to one quarter have lymphopenia or 
thrombocytopenia as well [24]. Thrombocytopenia in TB 
can result from immune-mediated destruction, hyper-
splenism and infiltration of the bone marrow [25]. While 
ferritin is usually moderately increased in TB, values in 
excess of 10,000  ng/mL have been described in miliary 
TB [24]. Our patient’s symptoms and findings coincided 
with the multiple sites from which M. tuberculosis was 
recovered, but could also represent organ damage due to 
HLH. Hence pollakiuria and renal failure could be  due 
to affection of kidneys and the urinary tract, history of 
diarrhea, colonic changes and abdominal fat tissue reac-
tion on CT due to affection of the intestines, and nota-
bly, dyspnea, pulmonary crepitation, respiratory failure 
and ground-glass opacities on CT due to affection of the 
lungs. The bone marrow biopsy confirmed evidence of 
both hemophagocytosis and TB. The pathophysiology of 
HLH related to TB is mainly unknown. Phagocytosis of 
M. tuberculosis by macrophages, and hence Th1-medi-
ated cytotoxicity, followed by release of a large quan-
tity of cytokines and chemokines are probably involved 
[11]. HLH due to TB has a high mortality rate, and most 
reports describe fatal outcome, particularly if other com-
plicating factors are present [11, 26, 27]. The treatment 
of HLH is challenging, and simultaneous immunosup-
pressive treatment for HLH combined with specific treat-
ment of the underlying condition is necessary [16]. Given 
the rarity of the disease, few studies describing treatment 
alternatives exist. In most treatment regimens, etoposide 
is combined with corticosteroids [16, 28, 29].
The greatest obstacle to a successful outcome for indi-
viduals with HLH is a delayed diagnosis. As soon as the 
diagnosis is suspected or confirmed, treatment should 
be initiated. The major aims for HLH therapy are to sup-
press the life-threatening inflammation and to treat the 
underlying cause. Therapy based on the HLH-94 and 
HLH-2004 protocols consists of a series of weekly treat-
ments with corticosteroids and etoposide, with the addi-
tion of intrathecal methotrexate and hydrocortisone 
for those with central nervous system (CNS) involve-
ment (14, 30). For patients with an underlying infection, 
treatment of the triggering condition should be initi-
ated simultaneously, as treatment of the trigger has the 
potential to remove the stimulus for immune activation. 
For the current case, the underlying condition, TB, was 
treated with rifampicin, isoniazid, pyrazinamide and eth-
ambutol. However, in the case of TB-triggered HLH, it 
is particularly challenging that the immunosuppressive 
treatment indicated for HLH can severely exacerbate the 
course of TB. In the absence of tuberculostatic drugs, the 
treatment for HLH would have impaired the patient’s 
immunity to an extent that could result in fulminant, dis-
seminated TB. Beyond this rare situation of HLH, mil-
iary TB should always be considered before instituting 
Page 8 of 9Trovik et al. J Med Case Reports          (2020) 14:217 
immunosuppressive treatment for febrile illnesses of sus-
pected immunological genesis. While treatment for TB 
was critical for the survival of the patient, therapy against 
HLH seemed appropriate as well, and in accordance with 
generally accepted treatment algorithms. This is sup-
ported by the fact that our patient had an improvement 
of his respiratory failure after treatment with steroids and 
anti-TB drugs was initiated, but only had improvement in 
his kidney and bone marrow failure after etoposide was 
added.
To conclude, TB-associated HLH is an exceedingly rare 
condition, but should be considered for patients with risk 
factors for TB presenting with severe signs of organ fail-
ure, and clinical or laboratory findings consistent with 
HLH. The incidence of TB is declining globally, but it 
is still highly endemic in some countries. Awareness of 
HLH as a complication of TB and other chronic infec-
tious diseases such as HIV, leishmaniasis and hepatitis is 
important for early diagnosis and adequate management.
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